References
- Varghese TK, Jr., Hofstetter WL, Rizk NP, et al. The society of thoracic surgeons guidelines on the diagnosis and staging of patients with esophageal cancer. Ann Thorac Surg. 2013;96(1):346–356.
- Wheeler JB, Reed CE. Epidemiology of esophageal cancer. Surg Clinics N America. 2012;92(5):1077–1087.
- Cellini F, Morganti AG, Di Matteoa FM, et al. Clinical management of gastroesophageal junction tumors: Past and recent evidences for the role of radiotherapy in the multidisciplinary approach. Rad Oncol. 2014;9:45.
- Kallman JB, Arsalla A, Park V, et al. Screening for hepatitis B, C and non-alcoholic fatty liver disease: A survey of community-based physicians. Alimentary Pharmaco Therapeutics. 2009;29(9):1019–1024.
- Strong VE, D'Amico TA, Kleinberg L, Ajani J. Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. JNCCN. 2013;11(1):60–66.
- Merkow RP, Bilimoria KY, McCarter MD, et al. Effect of histologic subtype on treatment and outcomes for esophageal cancer in the United States. Cancer. 2012;118(13):3268–3276.
- Botterweck AAM, Schouten LJ, Volovics A, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol. 2000;29:645–654.
- Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA: Cancer Journal Clin. 2013; Apr 12.
- Nieman DR, Peters JH. Treatment strategies for esophageal cancer. Gastroenterol Clin North Am. 2013;42(1):187–197.
- Siewert JR, Richards FM, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: Results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232:353–361.
- Fox MP, van Berkel V. Management of gastroesophageal junction tumors. Surg Clin North Am. 2012;92(5):1199–1212.
- McColl KE, Going JJ. Aetiology and classification of adenocarcinoma of the gastro-oesophageal junction/cardia. Gut. 2010;59(3):282–284.
- Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: Esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17(7):1721–1724.
- Allum WH, Blazeby JM, Griffin SM, et al. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60(11):1449–1472.
- National Comprehensive Cancer Network. NCCN Guidelines: Esophageal and Esophagogastric Junction Cancers; 2013. Available online at: www.nccn.org/professionals/physician_gls/f_guidelines.asp. Last accessed June 12, 2014.
- Chennat J KV, Ross AS, et al. Complete Barrett's eradication endoscopic mucosal resection: An effective treatment modality for high-grade dysplasia and intramucosal carcinoma—an American single-center experience. Am J Gastroenterol. 2009;104(11):2684–2692.
- Lordick F OK, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol. 2007;8(9):797–805.
- Shah MA. Unanswered questions in the management of gastroesophageal junction adenocarcinoma: an overview from the medical oncologist's perspective. American Society Clinical Oncology Education Book. ASCO; 2013.
- Cunningham D, Allum WH, Stenning SP, et al. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. NEJM. 2006;355:11–20.
- van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. NEJM. 2012;366(22):2074–2084.
- Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Peroperative chem(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junciton, and lower esophagus. Cochrane Databse Syst Rev. 2013;5.
- Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. NEJM. 2011;364(22):2128–2137.
- O'Malley KJ, Cook KF, Price MD, et al. Measuring Diagnosis: ICD Code Accuracy. Health services research. 2005;40(5):1620–1639.
- Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-neu-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697.